[Effect of recombinant human interleukin 11 on recovery of platelets after peripheral blood hematopoietic stem cell transplantation].
The aim of this study was to explore the effect of recombinant human interleukin 11 (rhIL-11) on platelet recovery after peripheral blood hematopoietic stem cell transplantation and its side-effects. 20 patients with hematologic malignancies treated by allogeneic peripheral blood stem cell transplantation (PBSCT) were randomly divided into test and control groups. The patients in test group were treated with rhIL-11 since the day 6 after PBSCT, while the patients in control group were given supporting treatment. The results showed that the average time of the platelet to recover to 20 x 10(9)/L was 22.8 days in test group and 27.3 days in control group (p < 0.01). The average time for platelet to recover to 50 x 10(9)/L was 25.7 days in test group, and 32.3 days in control group (p < 0.01). The average number of megakaryocytes was 15.6 in test group, and 7.8 in control group on day 30 after PBSCT (p < 0.01). In conclusion, the rhIL-11 is able to accelerate platelet recovery after peripheral blood hematopoietic stem cell transplantation.
Li
Jing-Dong
JD
Department of Hematology, The First Affiliated Hospital, Xinxiang Medical College, Weihui 453100, China. Ljd2004@126.com
Han
Xiao-Lin
XL
Wu
Sun
S
D000293:Adolescent; D000328:Adult; D001792:Blood Platelets / Q000187:drug effects*; D005260:Female; D006801:Humans; D017370:Interleukin-11 / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D010976:Platelet Count; D011994:Recombinant Proteins / Q000627:therapeutic use; D055815:Young Adult
D017370:Interleukin-11; D011994:Recombinant Proteins; C105308:oprelvekin